4 Hancock Street, Cambridge, MA 02139
The VHU® been shown to reduce time of manufacturing by 1/2 and increase viral vector yields by at least an order of magnitude compared to batch processes with suspension cells. By employing the VHU ® in perfusion mode for continuous harvesting of Viral Vectors or Vaccines the Cost of Goods can decrease by as much as 90%.
VHU ® Perfusion for reducing COGS by 90% compared to adherent cell process (eg. CF10)
Viral vectors and viral vaccines play an important role in current gene therapy and pandemic vaccine approaches.
Viral vectors like adenoviruses (Ad), or lentiviruses (LV) are the vehicles being developed for delivering genetic material in vaccine prophylaxis and gene therapy. Viral vaccines such as adenovirus to express the SARS-CoV-2 spike protein are the most advanced vaccines to combat the current Covid-19 pandemic. Adenovirus production in perfusion mode can reduce the manufacturing time by 1/2 for obtaining 1 billion doses compared to batch manufacturing.
The use of suspension cells to produce viral vectors/vaccines in perfusion mode offers an alternative solution to batch manufacturing which is gaining traction in the industry. Competing acoustic-based cell retention devices such as BioSep® are limited to R&D production scales. In addition, the current ATF perfusion systems cannot be used for the production of viral vectors because they do not allow the viral vectors (eg. Lentiviral (LV) or Adeno Associated Virus (AAV) to permeate through the hollow fiber membrane (S. Ansorge, et al. Scalable Lentiviral Vector Production using Stable Producer Cell Lines in Perfusion Mode, Poster No. 141, Cell Culture Engineering XVI, May 6-11, 2018).
Artemis Biosystems has developed a scalable production system based on the VHU® (US Patent 10,358,626 B2, Cattaneo and Spanjaard, 2019) to produce clinical or commercial quantities of viral vectors from mammalian cells in suspension culture such as HEK293 or MDCK cells. When using the VHU® in perfusion mode, viral vector/vaccine production is increased by at least 1-2 orders of magnitude (M. Cattaneo, ISBiotech, 9th Spring Meeting on Viral Vectors and Vaccines, Norforlk, VA, 2019). With the help of the VHU® the viral yield is increased by at least an order of magnitude and results in a 50% reduction in the time of manufacturing compared to batch processes.
Please get in touch by sending us an email at email@example.com, or call us at 617-674-2747 to discuss how VHU™ can solve your viral vector/vaccine production scale up problems from pilot to commercial scale